Evidence map›Paper›PMID 33027788›Full record

ArticleOncology2020

Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.

Reham Abdel-Wahab, Manal M Hassan, Bhawana George, Roberto Carmagnani Pestana, Lianchun Xiao, Sahin Lacin, Suayib Yalcin, Ahmed S Shalaby, Humaid O Al-Shamsi, Kanwal Raghav and 16 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Evaluating the role of preoperative serum insulin-like growth factor 1 as a predictor of survival and recurrence for patients with resectable hepatocellular carcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 5 countries.

Reham Abdel-WahabDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Manal M HassanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bhawana GeorgeDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roberto Carmagnani PestanaDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lianchun XiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sahin LacinDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Suayib YalcinHacettepe University Institute of Cancer, Ankara, Turkey.
Ahmed S ShalabyDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Humaid O Al-ShamsiMedical Oncology Department, Alzahra Hospital Dubai, Dubai, United Arab Emirates.
Kanwal RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Robert A WolffDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
James C YaoDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lauren GirardDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abedul HaqueDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dan G DudaSteele Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Simona DimaDan Setlacec Center of General Surgery and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Irinel PopescuDan Setlacec Center of General Surgery and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Hesham A ElghazalyDepartment of Clinical Oncology, Ain Shams University, Cairo, Egypt.
Jean-Nicolas VautheyDepartment of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Thomas A AloiaDepartment of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ching-Wei TzengDepartment of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yun Shin ChunDepartment of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Asif RashidDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey S MorrisDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hesham M AminDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ahmed O KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, akaseb@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USInstitutul Clinic Fundeni · ROAin Shams University · EGAssiut University · EGHacettepe University Hospital · TRMassachusetts General Hospital · USThe University of Texas Health Science Center at Houston · USUniversity of Sharjah · AE

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphomaR01CA151533 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIN, HESHAM M · 2011 to 2015
$1.6M
Molecular Epidemiology of Chronic Liver DiseasesK07CA106458 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HASSAN, MANAL METWALLY · 2005 to 2009
$681k
Novel Point-of-Care Tool to Predict Response to Sorafenib in Hepatocellular CarcinomaR21CA190945 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KASEB, AHMED · 2016 to 2017
$383k
Integrating plasma IGF-1 into novel classification of hepatocellular carcinomaR21CA170035 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KASEB, AHMED · 2012 to 2013
$366k
NCI NIH HHS K07 CA106458NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA151533NCI NIH HHS R21 CA170035NCI NIH HHS R21 CA190945
6 · The paper itself

Abstract

backgroundLiver reserve affects survival in hepatocellular carcinoma (HCC). Model for End-Stage Liver Disease (MELD) score is used to predict overall survival (OS) and to prioritize HCC patients on the transplantation waiting list, but more accurate models are needed. We hypothesized that integrating insulin-like growth factor 1 (IGF-1) levels into MELD score (MELD-IGF-1) improves OS prediction as compared to MELD.

methodsWe measured plasma IGF-1 levels in training (n = 310) and validation (n = 155) HCC cohorts and created MELD-IGF-1 score. Cox models were used to determine the association of MELD and MELD-IGF-1 with OS. Harrell's c-index was used to compare the predictive capacity.

resultsIGF-1 was significantly associated with OS in both cohorts. Patients with an IGF-1 level of ≤26 ng/mL in the training cohort and in the validation cohorts had significantly higher hazard ratios than patients with the same MELD but IGF-1 >26 ng/mL. In both cohorts, MELD-IGF-1 scores had higher c-indices (0.60 and 0.66) than MELD scores (0.58 and 0.60) (p < 0.001 in both cohorts). Overall, 26% of training and 52.9% of validation cohort patients were reclassified into different risk groups by MELD-IGF-1 (p < 0.001).

conclusionsAfter independent validation, the MELD-IGF-1 could be used to risk-stratify patients in clinical trials and for priority assignment for patients on liver transplantation waiting list.

Indexed as

Carcinoma, HepatocellularCohort StudiesFemaleHumansInsulin-Like Growth Factor ILiverLiver NeoplasmsMaleMiddle AgedPatient SelectionProportional Hazards ModelsRisk FactorsSeverity of Illness IndexIGF1 protein, humanInsulin-Like Growth Factor IHepatocellular carcinomaInsulin-like growth factor 1Liver transplantationMELD-IGF-1Model for End-Stage Liver Disease

Identifiers

PMID33027788
PMCPMC7704605
OpenAlexW3092394556

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.